Affiliation:
1. Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus
2. Belarusian State Medical University
Abstract
In experiments on male Wistar rats, the effect of synthetic derivatives of arginine-vasopressin (tetrapeptides N-Ac-DSer-Pro-DArg-Gly-NH2 (I) (1.0 μg/kg, i. n.), N-Ac-Trp -Pro-Arg-Gly-NH2 (II) (1.0 μg/kg, i. n.) on the dynamics of the level of anxiety (LA) and the ability to reproduce operant reactions (OR) against the background of 24-hour deprivation of the paradoxical phase of sleep (REM sleep deprivation) in rats. Statistically, N-Ac-Trp-Pro-Arg-Gly-NH2 significantly ( p < 0.05) reduced the LA of rats exposed to stress, increasing the proportion of individuals in the population that had spent time in the central square of the actometer chamber not less than 10 % of the total duration of actometry. The oligopeptide N-Ac-DSer-Pro-DArg-Gly-NH2 had a statistically significant ( p < 0.05) corrective effect on the ability to reproduce the developed OR of pressing the pedal in rodents (Wistar rats of an unranked population and Wistar individuals with low LA) subjected to REM sleep deprivation. Thus, both studied compounds did not cause cognitive impairment, and N-Ac-DSer-ProDArg-Gly-NH2 improved mnestic functions against the background of REM sleep deprivation. The results of assessing the level of general motor activity indicated the absence of side sedative effects in I (1.0 μg/kg) and II (1.0 μg/kg ‒ at a dose that causes an anxiolytic effect when administered II). The data obtained indicate the anxiolytic effect of N-Ac-Trp-Pro-Arg-GlyNH2, the positive mnemotropic effect of N-Ac-DSer-Pro-DArg-Gly-NH2, and a low likelihood of developing side effects in relation to the central nervous system against the background their applications.
Publisher
Publishing House Belorusskaya Nauka
Reference33 articles.
1. Garakani A., Murrough J. W., Freire R. C., Thom R. P., Larkin K., Buono F. D., Iosifescu D. V. Pharmacotherapy of anxiety disorders: Current and emerging treatment options. Frontiers in Psychiatry, 2020, vol. 11, art. 595584. https://doi.org/10.3389/fpsyt.2020.595584
2. Penninx B. W., Pine D. S., Holmes E. A., Reif A. Anxiety disorders. Lancet, 2021, vol. 397, no. 10277, pp. 914–927. https://doi.org/10.1016/S0140-6736(21)00359-7
3. Fedin A. I. Anxiety and depressive disorders in general practice. Pul’monologiya [Pulmonology], 2022, vol. 32, no. 2 (suppl.), pp. 35–41 (in Russian).
4. On approval of clinical protocols: Decree of the Ministry of Health of the Republic of Belarus, November 8, 2022, No. 108. National legal Internet portal of the Republic of Belarus. Available at: https://pravo.by/document/?guid=12551&p0=W22339960p (accessed 25.10.2023) (in Russian).
5. Goldschen-Ohm M. P. Benzodiazepine modulation of GABAA receptors: A mechanistic perspective. Biomolecules, 2022, vol. 12, no. 12, art. 1784. https://doi.org/10.3390/biom12121784